Tham Seng Kong

Dr. THAM earned his Bachelor of Medicine from Xiamen University, Doctor of Medicine (MD) Integrated Chinese Medicine & Western Clinical Medicine (Oncology) from Guangzhou University of Chinese Medicine (GUCM) and Doctor of Medicine (PHD) in Biomedical Engineering.

He is involved in ongoing extensive research on anti-aging cellular therapy since 2006. He works very closely with his Swiss and Asian counterparts in advancing the human understanding of cellular therapy and is eager to share his experiences in this field.

He also actively participates in cancer research. One of his important scientific breakthroughs is the discovery of penetrating tyrosinase inhibitor to reduce the production of melanin for skin beauty and whitening. He also described in his recent publication on the successful construction of retroviral transfection system that could be developed as a means of gene therapy for hepatic carcinoma.

Dr. Tham as Group Chief Executive Officer and Group Chief Research Scientist will be the main personality leading and driving the ALPS Group to greater heights towards recognition as a global biotechnology company serving humanity.